ExodusPoint Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

ExodusPoint Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-604	Closed	-$17K	–	2601
2022 Q1	$17K	Sell	604 -8,521	-93%	-$310K	﹤0.01%	2109
2021 Q4	$414K	Buy	9,125 +939	+11%	+$63.2K	﹤0.01%	1513
2021 Q3	$683K	Buy	+8,186	New	+$677K	0.01%	1228
2021 Q2	–	Sell	-4,728	Closed	-$787K	–	2941
2021 Q1	$787K	Buy	+4,728	New	+$625K	0.01%	1062
2019 Q4	–	Sell	-660	Closed	-$66K	–	1981
2019 Q3	$66K	Buy	+660	New	+$67.6K	﹤0.01%	1263

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

ExodusPoint Capital Management's ONCT Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 604 shares — an estimated $17K sold.

ExodusPoint Capital Management first reported a position in ONCT in Q3 2019 and held it in 5 quarters. The position peaked at $787K in Q1 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

ExodusPoint Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 604 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $17K.
ExodusPoint Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
ExodusPoint Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $787K in Q1 2021.
75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.